Effects of Macronutrient Excess and composition on oxidative stress: Relevance to diabetes and cardiovascular disease

Current Atherosclerosis Reports

Volumn 8, Issue 6, 2006, Pages 472-476

  Ceriello, Antonio ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ANTIOXIDANT ACTIVITY; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SYNTHESIS; LIFESTYLE; MACRONUTRIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PHYSICAL ACTIVITY; PREVALENCE; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; NUTRITION ASSESSMENT; OXIDATIVE STRESS; RISK FACTORS;

EID: 33750719099     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0022-z     Document Type: Review

References (44)

1. Amos A, McCarthy D, Zimmet P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997, 14(Suppl 5): S1-S85.
2. Rosembloom AL, Joe JR, Young RS, Winter WE: Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999, 22:345-354.
3. Kannel WB, McGee DL: Diabetes and cardiovascular diseases. The Framingham Study. JAMA 1979, 241:2035-2038.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
5. Hu FB, Stampfer MJ, Haffner SM, et al.: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25:1129-1134.
6. Stern MP: Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995, 44:369-374.
7. Kahan SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003, 46:3-19.
8. Haffner SM, Stern MP, Hazuda HP, et al.: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263:2893-2898.
9. Sinha R, Fisch G, Teague B, et al.: Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002, 346:802-810.
10. Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
11. Balkau B, Bertrais S, Ducimetiere P, Eschwege E: Is there a glycaemic threshold for mortality risk? Diabetes Care 1999; 22:696-699.
12. Ceriello A: Acute hyperglycaemia and oxidative stress generation. Diabetes Med 1997, 14(Suppl 3):S45-S49.
13. Heilbronn LK, Ravussin E: Calorie restriction and aging: review of the literature and implications for studies in humans. Am J Clin Nutr 2003, 78:361-369.
14. Adams V, Linke A, Krankel N, et al.: Impact of regular physical activity on the NAD(P)H oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation 2005, 111:555-562.
15. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and B-cell dysfunction? Diabetes 2003, 52:1-8.
16. Williamson JR, Cooper RH: Regulation of the citric acid cycle in mammalian systems. FEBS Lett 1980, 117(Suppl): K73-K85.
17. Tiedge M, Lortz S, Drinkgern J, Lenzen S: Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin producing cells. Diabetes 1997, 46:1733-1742.
18. Robertson RP, Harmon J, Tran PO, et al.: Glucose toxicity in B-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003, 52:581-587.
19. Sakai K, Matsumoto K, Nishikawa T, et al.: Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic beta-cells. Biochem Biophys Res Commun 2003, 300:216-222.
20. Lameloise N, Muzzin P, Prentki M, Assimacopoulos-Jeannet F: Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes 2001, 50:803-809.
21. Mattiasson G, Sullivan PG: The emerging functions of UCP2 in health, disease, and therapeutics. Antioxid Redox Signal 2006, 8:1-38.
22. Pecqueur C, Alves-Guerra MC, Gelly C, et al.: Uncoupling protein 2, in vivo distribution, induction upon oxidative stress, and evidence for translational regulation. J Biol Chem 2001, 276:8705-8712.
23. Carlsson C, Borg LA, Welsh N: Sodium palmitate induces partial mitochondrial uncoupling and reactive oxygen species in rat pancreatic islets in vitro. Endocrinology 1999, 140:3422-3428.
24. Piro S, Anello M, Di Pietro C, et al.: Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism 2002, 51:1340-1347.
25. Heitzer T, Schlinzig T, Krohn K, et al.: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104:2673-2678.
26. Tesfamariam B, Cohen RA: Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992, 263:H321-H326.
27. Marfella R, Verrazzo G, Acampora R, et al.: Glutathione reverses systemic hemodynamic changes by acute hyperglycemia in healthy subjects. Am J Physiol 1995, 268: E1167-E1173.
28. Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
29. Pleiner J, Schaller G, Mittermayer F, et al.: FFA-induced endothelial dysfunction can be corrected by vitamin C. J Clin Endocrinol Metab 2002, 87:2913-2917.
30. Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004, 24:816-823.
31. Bast A, Wolf G, Oberbaumer I, Walther R: Oxidative and nitrosative stress induces peroxiredoxins in pancreatic beta cells. Diabetologia 2002, 45:867-876.
32. Sakuraba H, Mizukami H, Yagihashi N, et al.: Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002, 45:85-96.
33. Johnstone MT, Creager SJ, Scales KM, et al.: Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993, 88:2510-2516.
34. McVeigh GE, Brennan GM, Johnston GD, et al.: Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1992, 35:771-776.
35. Ceriello A: New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003, 26:1589-1596.
36. Marchioli R, Schweiger C, Levantesi G, et al.: Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. Lipids 2001, 36:S53-S63.
37. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/ reperfusion injury. Pharmacol Rev 2001, 53:135-159.
38. Smith RA, Porteous CM, Gane AM, Murphy MP: Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci U S A 2003, 100:5407-5412.
39. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
40. Münzel T, Keaney JF Jr: Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 2001, 104:1571-1579.
41. Ceriello A, Motz E: Angiotensin-receptor blockers, type 2 diabetes, and renoprotection [letter]. N Engl J Med 2002, 346:705-707.
42. Da Ros R, Assaloni R, Ceriello A: The preventive antioxidant action of thiazolinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabetes Med 2004, 21:1249-1252.
43. Ceriello A, Morocutti A, Mercuri F, et al.: Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes 2000, 49:2170-2177.
44. Hodgkinson AD, Bartlett T, Oates PJ, et al.: The response of antioxidant genes to hyperglycemia is abnormal in patients with type 1 diabetes and diabetic nephropathy. Diabetes 2003, 52:846-851.